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Background. It is well known that serum creatinine may be
used as a marker of renal function only if taking into account
factors that influence creatinine production, such as age, gender,
and weight. Serum cystatin C has been proposed as a potentially
superior marker than serum creatinine, because serum cystatin
C level is believed to be produced at a constant rate and not
to be affected by such factors. However, there are limited data
on factors that may influence serum cystatin C levels, and there
are limited data comparing cystatin C-based estimates of renal
function with creatinine-based estimates that adjust for such
factors, especially in individuals with normal, or mildly reduced,
renal function.
Methods. This was a cross-sectional study of 8058 inhabitants
of the city of Groningen, The Netherlands, 28 to 75 years of age.
Serum cystatin C and serum creatinine levels were measured,
and creatinine clearance was determined from the average of
two separate 24-hour urine collections. We performed multi-
variate analyses to identify factors independently associated
with serum cystatin C levels after adjusting for creatinine clear-
ance. Then, partial Spearman correlations were obtained after
adjusting for factors that may influence serum cystatin C and
creatinine levels. We also compared the goodness-of-fit (R2) of
different multivariate linear regression models including serum
cystatin C level and serum creatinine level for the outcome of
creatinine clearance.
Results. Older age, male gender, greater weight, greater
height, current cigarette smoking, and higher serum C-reactive
protein (CRP) levels were independently associated with higher
serum cystatin C levels after adjusting for creatinine clearance.
After adjusting for age, weight, and gender, the partial Spear-
man correlations between creatinine and, respectively, serum
cystatin C level and serum creatinine level were −0.29 (P <
0.001) and –0.42 (P < 0.001), respectively. The R2 values for
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serum cystatin C level and serum creatinine level adjusted for
age, weight, and gender were 0.38 and 0.42, respectively. The
addition of cigarette smoking and serum CRP levels did not im-
prove the R2 value for the multivariate serum cystatin C-based
model.
Conclusion. Serum cystatin C appears to be influenced by
factors other than renal function alone. In addition, we found
no evidence that multivariate serum cystatin C–based estimates
of renal function are superior to multivariate serum creatinine-
based estimates.
Serum creatinine level is commonly used to estimate
renal function. Serum creatinine level, though, is not only
determined by its renal excretion, but also by its produc-
tion in muscular tissue, which is dependent on age, weight,
and gender. Therefore, when using serum creatinine level
to estimate renal function, one needs to adjust for these
factors. Thus, these parameters are incorporated into the
Cockcroft-Gault formula for estimating renal function
[1].
Serum cystatin C level is another marker of renal func-
tion that has been proposed as potentially superior to
serum creatinine level for estimating renal function, be-
cause it is thought to be produced at a constant rate by
most nucleated cells [2]. Moreover, cystatin C production
has been reported to be not affected by age [3, 4], gender
[3, 5], or muscle mass [6]. Cystatin C is freely filtered at the
level of the glomerulus and virtually all is reabsorbed and
metabolized by the proximal tubular cells [7]. Therefore,
assuming constant cellular production, serum cystatin C
level has the potential to be an excellent surrogate marker
of glomerular filtration rate (GFR).
A recent meta-analysis concluded that serum cystatin C
level is a superior marker of renal function compared with
serum creatinine level [8]. However, this meta-analysis
did not adjust for other factors that may affect serum
creatinine and serum cystatin C levels by influencing the
production of the marker. There are a few small studies
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comparing the performance of serum cystatin C level and
serum creatinine level for estimating renal function that
take into account such factors, but these studies have had
conflicting results [9–14]. Thus, to address this paucity of
information, we analyzed the performance characteristics
of serum cystatin C and creatinine levels for estimating
measured creatinine clearance utilizing data collected in
the Prevention of Renal and Vascular End-Stage Disease
(PREVEND) cohort, a population-based sample of 8592
individuals from Groningen, The Netherlands, designed
to study the impact albuminuria on cardiovascular and re-
nal diseases in the general population. We incorporated
clinical and laboratory information into our estimates of
creatinine clearance in order to improve the correlations
and goodness-of-fit of serum cystatin C and serum creati-
nine levels for estimating measured creatinine clearance.
We specifically addressed whether factors that are known
to influence serum creatinine-based estimates of creati-
nine clearance, such as age, gender, and weight, as well as
other cardiovascular risk factors, such as C-reactive pro-
tein (CRP) level and smoking, could improve the predic-




We utilized data from the PREVEND cohort. Details
of this study have been presented elsewhere [15]. In 1997
and 1998, all inhabitants aged 28 to 75 years of the city
of Groningen, The Netherlands, were asked to answer a
short questionnaire and send in a morning urine sample.
Pregnancy and insulin-requiring diabetes were exclusion
criteria. We received a response from 40,856 individu-
als. We selected all individuals with a urine albumin con-
centration ≥10 mg/L (N = 7768) and a random sample
of 3395 individuals with a urine albumin concentration
<10 mg/L. These individuals were invited to an outpa-
tient medical clinic for further screening. All participants
who came for further screening completed a more de-
tailed questionnaire that asked about demographic and
medical information, and fasting blood samples were
obtained to measure serum cystatin C level, serum
creatinine level, and other laboratory parameters. An-
thropometric information was recorded, blood pressure
was measured during 10 minutes on two separate days
and two consecutive 24-hour urine collections were ob-
tained to measure creatinine clearance. The screening
program was completed by 8592 individuals. For the
present study we excluded 534 individuals who were miss-
ing information on serum cystatin C level, serum creati-
nine level, or creatinine clearance. This left a total of 8058
individuals for our analyses. Less than 5% of individuals
(425/8592) in the total cohort reported a race other than
Caucasian.
Measurement of serum cystatin C, serum creatinine, and
creatinine clearance
Serum cystatin C level was measured by nephelom-
etry (BN II N) (Dade Behring Diagnostic, Marburg,
Germany) and reported as milligrams per liter. The intra-
and interassay coefficients of variation were <4.1% and
<3.3%, respectively. Serum creatinine level was mea-
sured in one laboratory using an automated enzymatic
method (Eastman Kodak, Rochester, NY, USA). The
intra- and interassay variation coefficient of serum crea-
tinine were respectively 0.9% and 1.1%. For urinary cre-
atinine the coefficients were respectively 0.9% and 2.9%.
Each 24-hour urine creatinine clearance was calculated
by multiplying the mean of day 1 and 2 urine creatinine
concentration by the 24-hour urine volume divided by
serum creatinine. For all analyses, we utilized the mean
of the two creatinine clearance measurements. The units
for creatinine clearance are mL/min.
Measurement of other factors
Weight was measured at the outpatient clinic to the
nearest 0.5 kg with a Seca balance scale (Seca Vogel &
Halke GmbH & Co, Hamburg, Germany). Height was
measured to the nearest 0.5 cm. Smoking was assessed
by questionnaire. Diabetes was defined as a fasting glu-
cose level of ≥7.0 mmol/L, a nonfasting glucose level
≥11.1 mmol/L, or the use of oral antidiabetic medica-
tion. Hyperlipidemia was defined as follows: (1) a serum
cholesterol of ≥6.5 mmol/L; (2) a serum cholesterol
≥5.0 mmol/L if an individual had a prior myocardial in-
farction; or (3) the use of lipid-lowering medication. Hy-
pertension was defined as a systolic blood pressure of
≥140 mm Hg, a diastolic blood pressure of ≥90 mm Hg
or the use of lipid-lowering medication. CRP was mea-
sured by nephelometry with a threshold of 0.175 mg/L
and intra- and interassay coefficients of <4.4% and
5.7% respectively. An elevated CRP level was defined as
≥3 mg/L [16].
Urinary albumin concentration was determined by
nephelometry with a threshold of 2.3 mg/L and intra- and
interassay coefficients of variation of less than 2.2% and
2.6%, respectively (Dade Behring Diagnostic). For the
calculation of the prevalence of elevated urinary albumin
excretion (UAE), we excluded subjects with leucocyturia
and erythrocyturia.
Obesity was defined as a body mass index (BMI)
≥30 kg/m2.
Statistical analysis
For continuous variables, the mean, standard deviation
and 5% to 95% range were calculated. For categoric vari-
ables, we examined the percentage of individuals in each
category. We identified factors associated with serum
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cystatin C levels using multivariate linear regression anal-
yses with the following prespecified covariates: creatinine
clearance (continuous), age (years), gender (male or fe-
male), weight (kg), height (m), current smoking (yes or
no), diabetes (yes or no), hyperlipidemia (yes or no), hy-
pertension (yes or no), and elevated CRP level. Since
serum cystatin C levels were not normally distributed on
univariate analysis, the natural logarithm of serum cys-
tatin C level was used for these analyses. We performed
similar analyses using the natural logarithm of serum cre-
atinine level.
Next, we examined the Spearman correlations between
both serum cystatin C and serum creatinine levels and
creatinine clearance, and we examined partial Spearman
correlations adjusted for age, gender, weight, height, CRP
level, and smoking status. We repeated these analyses ex-
cluding individuals whose two 24-hour creatinine clear-
ance measurements differed by more than 20%.
After assessing the normality assumption for creatinine
clearance, we performed linear regression to examine the
R2 values of different models to predict creatinine clear-
ance. The R2 value is defined as the regression sum of
squares divided by the total sum of squares, and can be
thought of the proportion of the variance of the depen-
dent variable explained by the independent variables. We
examined the R2 values for both serum cystatin C level
and serum creatinine level individually, and we exam-
ined different multivariate models that included serum
cystatin C and serum creatinine level. We also examined
multivariate models of creatinine clearance excluding in-
dividuals whose two 24-hour creatinine clearance values
differed by more than 20%.
Finally, we utilized multivariate receiver-operating
characteristic (ROC) analyses to examine the ability of
serum cystatin C and serum creatinine levels to predict a
creatinine clearance of <60 mL/min or <90 mL/min. Us-
ing these data, we were able to compare the areas under
the curve (AUC) for these different estimates of renal
function.
All analyses were performed using SAS Statistical Soft-
ware version 8.2 (SAS Institute, Cary, NC, USA).
RESULTS
Characteristics of the participants are presented in
Table 1. Tables 2 and 3 present participant characteris-
tics stratified by serum cystatin C and serum creatinine
quintiles, respectively. On multivariate linear regression
analysis, also adjusting for creatinine clearance, older
age, male gender, greater weight, greater height, cur-
rent cigarette smoking, and a high CRP level were each
independently positively associated with serum cystatin
C levels. Hyperlipidemia, hypertension, and diabetes
were not significantly associated with serum cystatin C
levels. As expected, male gender, greater weight, and
Table 1. Demographic and laboratory data for individuals in the
Prevention of Renal and Vascular End-Stage Disease (PREVEND)
cohort with percentages, means, standard deviations, and 5% to 95%
ranges (total N = 8058)
Age years 49 ± 13 (range 31–71)
Male % 50
Serum cystatin C mg/L 0.80 ± 0.21 (range 0.57–1.12)
Serum creatinine mg/dL 0.95 ± 0.22 (range 0.72–1.24)
Creatinine clearance mL/min 102 ± 27 (range 63–148)
Weight kg 78 ± 14 (range 58–104)
Body mass index (≥30 kg/m2) % 15
C-reactive protein (≥3 mg/L) % 25




Urinary albumin excretion 14
(≥30 mg/day) %
The mean, standard deviation, and 95% range are presented for continuous
variables, and percentages are reported for categorical variables.
To convert mg/dL to umol/L multiply by 88.402.
greater height, but similarly also hyperlipidemia and hy-
pertension were each independently positively associated
with serum creatinine levels after adjusting for creati-
nine clearance. Similarly older age, but also diabetes and
cigarette smoking were each independently negatively as-
sociated with serum creatinine levels. CRP level was not
significantly associated with serum creatinine level.
Serum cystatin C and serum creatinine level were pos-
itively correlated (r = 0.44, P < 0.001). Serum cystatin
C level alone (r = −0.23, P < 0.001) was better cor-
related with creatinine clearance than serum creatinine
level alone (r = −0.08, P < 0.001). Serum cystatin C
level was highly correlated with age, moderately corre-
lated with weight and serum CRP level and weakly cor-
related with height (Table 4). Serum creatinine level was
highly correlated with weight and height, moderately cor-
related with age and weakly correlated with serum CRP
level (Table 4). When we examined the partial correla-
tions between both serum cystatin C level and serum cre-
atinine level with creatinine clearance adjusted for age,
weight, and gender, the correlations for serum cystatin C
level and serum creatinine level each improved; however,
serum creatinine level (r = −0.42, P < 0.001) was better
correlated with creatinine clearance than serum cystatin
C level (r = −0.29, P < 0.001). When we added CRP level
and current cigarette smoking (the additional factors in-
dependently associated with serum cystatin C levels), the
correlation between serum cystatin C level and creatinine
clearance did not change.
The R2 values for serum cystatin C level and serum
creatinine level alone were both low (Table 5). The addi-
tion of age, weight, and gender increased the R2 value for
both serum cystatin C level and serum creatinine level
(Table 5). The addition of height, CRP level, cigarette
smoking, diabetes, hypertension, and hypercholes-
terolemia to the models including age, weight, and
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Table 2. Demographic and laboratory data for individuals in the of Renal and Vascular End-Stage Disease (PREVEND) cohort stratified by
cystatin C quintile (total N = 8058)
Quintiles of cystatin C
1 2 3 4 5
Serum cystatin C level mg/L 0.58 ± 0.10 0.71 ± 0.02 0.78 ± 0.02 0.86 ± 0.03 1.08 ± 0.28
Minimum 0.05 0.67 0.75 0.82 0.91
Maximun 0.66 0.74 0.81 0.90 6.15
Age years 43 ± 10 45 ± 11 48 ± 12 51 ± 13 58 ± 12
Male % 31 44 52 59 64
Weight kg 73 ± 14 77 ± 14 79 ± 14 81 ± 14 82 ± 14
Body mass index (≥30 kg/m2) % 10 13 16 17 20
C-reactive protein (≥3 mg/L) % 17 21 22 26 38
Current smoker % 28 35 38 43 43
Diabetes % 3 3 3 4 6
Hyperlipidemia % 17 21 25 30 36
Hypertension % 19 23 29 35 53
Urinary albumin exretion (≥30 mg/day) % 10 9 13 14 25
Serum creatinine mg/dL 0.86 ± 0.13 0.90 ± 0.13 0.93 ± 0.13 0.97 ± 0.14 1.09 ± 0.39
Measured creatinine clearance mL/min 107 ± 26 107 ± 26 106 ± 26 102 ± 25 89 ± 26
The mean and standard deviation are presented for continuous variables, and percentages are reported for categorical variables.
To convert mg/dL to umol/L multiply by 88.402.
Table 3. Demographic and laboratory data for individuals in the of Renal and Vascular End-Stage Disease (PREVEND) cohort stratified by
creatinine quintile (total N = 8058)
Quintiles of creatinine
1 2 3 4 5
Serum creatinine mg/dL 0.74 ± 0.05 0.85 ± 0.02 0.93 ± 0.02 1.02 ± 0.03 1.21 ± 0.35
Minimum 0.49 0.81 0.89 0.97 1.07
Maximum 0.80 0.88 0.96 1.06 11.8
Age years 47 ± 12 47 ± 12 49 ± 13 50 ± 13 54 ± 13
Male % 10 25 49 73 90
Weight kg 72 ± 14 74 ± 14 78 ± 14 82 ± 13 85 ± 13
Body mass index (≥30 kg/m2) % 17 14 14 16 17
C-reactive protein (≥3 mg/L) % 28 24 23 23 26
Current smoker % 42 41 38 35 32
Diabetes % 4 3 3 3 5
Hyperlipidemia % 22 21 25 28 33
Hypertension % 25 24 29 32 48
Urinary albumin exretion (≥30 mg/day) % 11 9 12 13 25
Cystatin C mg/L 0.71 ± 0.15 0.75 ± 0.16 0.79 ± 0.18 0.82 ± 0.18 0.93 ± 0.30
Measured creatinine clearance mL/min 105 ± 26 102 ± 26 103 ± 27 106 ± 27 96 ± 27
The mean and standard deviation are presented for continuous variables, and percentages are reported for categorical variables.
To convert mg/dL to umol/L multiply by 88.402.
Table 4. Spearman correlations between cystatin C, creatinine, age,
weight, height, and C-reactive protein level (total N = 8058)
Age Weight Height C-reactive
years kg m protein mg/L
Cystatin C mg/L 0.41 0.22 0.08 0.26
Creatinine mg/dL 0.18 0.37 0.41 0.03
All P values for reported correlation <0.001.
gender, had no substantial impact on the R2 values for
serum cystatin C level or serum creatinine level. When we
limited the analyses to individuals whose two measured
creatinine clearance values differed by ≤20%, the R2 ad-
justed for age, weight, and gender improved from 0.38 to
0.46 for serum cystatin C level, and from 0.42 to 0.56 for
serum creatinine level.
Table 5. R2 values for different models to estimate 24-hour creatinine
clearance using serum cystatin C and creatinine (total N = 8058)
Cystatin C Creatinine
Alone 0.06 0.03
+ age 0.10 0.09
+ age and weight 0.35 0.35
+ age, weight, and gender 0.38 0.42
When we constructed ROC curves, the AUC values
were 0.71 for serum cystatin C level alone and 0.66 for
serum creatinine level alone for predicting a measured
creatinine clearance < 60 mL/min. The AUC for serum
cystatin C level adjusted for age, weight, and gender was
0.79, and the addition of CRP level and smoking status
did not improve the AUC. The AUC for serum creatinine
level adjusting for age, weight, and gender was 0.81. The
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AUC values were similar when we examined the predic-
tion of a measured creatinine clearance <90 mL/min.
DISCUSSION
In a general population sample, factors related to
serum cystatin C production and/or catabolism might
have more influence on serum cystatin C levels than GFR.
Therefore, it is important to note that not only older age,
male gender, and greater weight, and height but also cur-
rent cigarette smoking and higher CRP levels were inde-
pendently associated with higher serum cystatin C levels
after adjusting for creatinine clearance. These associa-
tions are thus not due to the fact that factors as obesity
[17–20], smoking [21, 22] and CRP [23, 24] are related
to renal function. They, in contrast, indicate that these
factors may influence cystatin C independent of their ef-
fects on renal function.
The association between age and serum cystatin C lev-
els contrasts with some reports [3, 4], although other stud-
ies have shown that serum cystatin C levels are higher
in older individuals [25, 26]. The observed associations
between male gender, greater weight and smoking and
higher serum cystatin C levels are consistent with the ob-
servations of Galteau et al [26], but that study did not
adjust for level of renal function. Wase´n et al [27] studied
elderly subjects and concluded that (cardiovascular) risk
factors are associated with both cystatin C and serum cre-
atinine although their R2 was higher for cystatin C. Again
they did not adjust for level of renal function. The uni-
variate association between higher serum cystatin C lev-
els and higher CRP levels may be partially explained by
the fact that obesity [28–31] and smoking [32, 33] are both
associated with higher CRP levels. However, the associ-
ation between serum cystatin C level and CRP remained
significant after adjusting for other factors, so serum cys-
tatin C may also be a biomarker of inflammation [34–36].
Thus, contrary to many reports, serum cystatin C levels
do appear to be influenced by multiple factors other than
renal function.
We found that serum cystatin C level alone was
a better predictor of creatinine clearance than serum
creatinine level, as assessed by the correlation with crea-
tinine clearance, the goodness-of-fit statistic (R2), and the
AUC of the ROC curve. However, when we incorporated
clinical information such as age, weight, and gender into
our models, serum cystatin C level did not perform bet-
ter than serum creatinine level for predicting creatinine
clearance. Our data also show that taking into account
age, weight, and gender improved the predictive perfor-
mance of serum cystatin C level, albeit to a smaller extent
than serum creatinine level. Thus, caution must be used
when interpreting cystatin C levels alone.
The observation that serum cystatin C level alone is
superior to serum creatinine level alone for predicting
creatinine clearance is not surprising, given the published
literature on this topic. However, the correlations we ob-
served were smaller than the published literature in in-
dividuals with chronic kidney disease. For example, Coll
et al [9] observed a correlation of 0.77 between 1/cys-
tatin C and iothalamate clearance and 0.73 between
1/serum creatinine and iothalamate clearance. In this
same study, the authors reported a correlation of 0.74
between 24-hour creatinine clearance and iothalamate
clearance. Assuming the correlations between serum cys-
tatin C and serum creatinine and creatinine clearance
would be slightly less than the correlation between these
biomarkers and GFR, these correlations are still much
higher than what we observed. Other authors have re-
ported that the correlations between both serum cystatin
C and serum creatinine level and GFR are much less in
individuals with a normal GFR [12, 13], which may ex-
plain why the correlations we observed are lower than
some of the reported literature on this topic.
The most important limitation of our analyses is that
we used 24-hour creatinine clearance to estimate renal
function instead of directly measuring GFR. It would be
logistically difficult to obtain true GFR measurements in
such a large population. We, however, feel that the use
of creatinine clearance as the golden standard for renal
function measurement does not diminish the certainty
of our conclusions regarding imperfections of serum cys-
tatin C versus serum creatinine as measure of renal func-
tion, as both the correlation between serum cystatin C
and creatinine clearance and between serum creatinine
and creatinine clearance improved comparably by the ex-
clusion of the outliers. This limitation is counterbalanced
by the large population and our ability to examine a large
number of factors that could potentially influence serum
cystatin C and serum creatinine levels. Another potential
limitation is generalizability. This population was almost
exclusively Caucasian, so these results may not be gener-
alized to other racial groups. It is also possible that we may
have overlooked some factors that may influence serum
cystatin C levels, because the literature on this topic is
limited.
These results suggest that serum cystatin C level should
not be used to estimate renal function unless one accounts
for other factors that may influence serum cystatin C lev-
els. In addition, serum cystatin C-based estimates of renal
function that incorporate other factors that may influence
serum cystatin C level, such as age, weight, gender, CRP
level, and smoking, do not appear to be superior to serum
creatinine-based estimates of renal function.
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